Diabetes treatment may provide protection against endometrial cancer.

Current article ratings:
Patients / public:healthcare Prof:
Under the direction of Warwick medical school at the University of Warwick, research has found that used for the treatment of diabetes and also in women with Polycystic syndrome (PCOS), vary metformin, a drug treatment can potentially against endometrial cancer.

Endometrial cancer is the most common malignancy of the female genital tract and the fourth most common cancer in women in the United Kingdom and the United States. Up to one-third of the PCOS have women also Endometrial hyperplasia, which in turn predisposes women to endometrial cancer. PCOS affects 5% - 10% of women of childbearing age, where metformin improves ameliorates insulin resistance and hyperinsulinemia in these women, but also long-term use of metformin ovulation and menstrual regularity.

Recent research has found that metformin has anti-cancer properties such as in breast cancer. In the face of this insulin resistance, States, such as obesity, diabetes, and PCOS are the effects of metformin more at risk of developing endometrial cancer, Warwick researchers examined treatment for endometrial cancer cells. The researchers used serum from control and PCOS (before and after metformin treatment) themes and basic experiments on endometrial cancer cells carried out. The experiments resulted in a decrease in the endometrial cancer cell invasion in Sera of metformin PCOS treated women.

The researchers found that samples serum samples of PCOS women who had completed the 6-month metformin, that the proliferation of endometrial cancer cells around 25 was % as in the serum lower of PCOS women, which are not, that the treatment had begun.

Tan, at Warwick medical school said the investigators, Dr. Harpal Randeva and Dr. bee K:

"We are very happy about our findings, that the significant impact of metformin therapy use on human endometrial cancer cells reveal." However it is advisable to research further to explore if metformin would be actually useful clinically as an adjuvant treatment in endometrial cancer; "This should be handled by one randomized controlled trial."

Notes

-The scientific essay has been published in the journal of clinical endocrinology & Stoffwechsel-doi:10.1210/jc.2010-1803 and is entitled metformin treatment practice Antiinvasive and anti method metastatic domestic effects in cells of human endometrial carcinoma by bee k. Tan, Raghu Adya, Jing Chen, Hendrik LehnertSant Louis j.-cassia and Harpal S. Randeva

-The researchers were from: the University of Warwick Warwick medical school (B.K.T., r.a., j.c., h.l., L.J.S.C., H.S.R.); the Department of reproductive medicine and surgery of Addenbrooke's Hospital, Cambridge University hospitals national health service Foundation Trust, Cambridge (B.K.T.); University of Lübeck medical school, (h.l.); and the Department of obstetrics & gynecology (University Hospital, University hospitals Coventry and Warwickshire national health service trust, Coventry, (L.J.S.C.).) Dr. Dennis Heutling, provided by the Division of Endocrinology Metabolism, Magdeburg University Hospital, Magdeburg, the clinical samples for this study.

Source:
University of Warwick